

UNIVERSITY OF PENNSYLVANIA - SCHOOL OF MEDICINE
Curriculum Vitae

January, 2024

Henry Glick Ph.D.

Address: 108 Calle Paula
Santa Fe, NM 87505
(215) 888-7910 - phone
Hag0407@dca.net

Education:

Sept. 1977- May 1999	Ph.D. University of Pennsylvania (Public Policy Analysis)
Sept. 1977- May 1982	M.A. University of Pennsylvania (Public Policy Analysis)
Sept. 1975- May 1976--	SUNY at Binghamton (Graduate studies, History and Philosophy of the Social and Behavioral Sciences)
Sept. 1971- May 1975	B.A. Hamilton College (Philosophy)

Military Service: None

Faculty Appointments:

July 2001- June 2006 Assistant Professor of Medicine, School of Medicine, University of

Pennsylvania

- May 2002-June 2006 Assistant Professor of Health Care Systems (secondary appointment), Wharton School, University of Pennsylvania
- July 2006 - June 2011 Associate Professor of Medicine, School of Medicine, University of Pennsylvania
- July 2006 - June 2011 Associate Professor of Health Care Systems (secondary appointment), Wharton School, University of Pennsylvania
- July 2011 – May 2023 Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
- July 2011 – May 2023 Professor of Health Care Systems (secondary appointment), Wharton School, University of Pennsylvania
- May 2023 – Current Emeritus Professor of Medicine, Perelman School of Medicine, University of Pennsylvania

Hospital and Administrative Appointments:

- Jan 1991-June 2001 Manager Research Project B, Division of General Internal Medicine, University of Pennsylvania
- Jan 1985- Dec. 1990 Research Specialist 4, Division of General Internal Medicine, University of Pennsylvania
- July 2008 – July 2012 Director, Cost-Effectiveness Analysis, Leonard Davis Institute of Health Economics Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania

Other Positions

- 1983-1984 Policy Analyst, Leonard Davis Institute of Health Economics, University of Pennsylvania
- 1982-1983 Staff Director, Committee on Primary Care, Mayor=s Commission on Health in the Eighties, Philadelphia, Pennsylvania

- 1978-1981 Health Research Analyst, Government Studies and Systems, Philadelphia, Pennsylvania
- 1976-1978 Benefit-Cost Research Analyst, Mathematica Policy Research, Princeton, New Jersey

Specialty Certification: None

Licensure: None

Awards, Honors and Membership in Honorary Societies:

- June 2000 Award for best poster, "Examining Hospital Length of Stay (LOS) of Patients with Suspected or Proven Methicillin-Resistant Staphylococcus Species Infections: A randomized Multi-Center Trial Comparing Linezolid with Vancomycin" (Pinto L, Li Z, Willke RJ, Rittenhouse BE, Hafkin B, Glick HA) at the annual meeting of the International Society of Technology Assessment in Health Care, The Haig, Netherlands.
- March 1999 Honorary member of the Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.
- June 1995 FHP prize for the second best paper published in volume 10 of the International Journal of Technology Assessment in Health Care (Shimbo T, Glick H, Eisenberg JM. Cost-Effectiveness Analysis of Strategies for Colorectal Cancer Screening in Japan. International Journal of Technology Assessment in Health Care, 1994;10:359-375), The International Society for Technology Assessment in Health Care.
- May 1990 Henry Christian Award for the highest scoring abstract in a subspecialty field (Schulman KA, Kinosian BP, Jacobson TA, Glick H, Willian MK, Koffer H, Eisenberg JM. Cost-Effectiveness of High Blood Cholesterol Reduction: Methods and Results. Clinical Research. 1990;38:702A), American Federation for Clinical Research, National Meeting.
- May 1984 Health Applications Section Spotlight Prize, Operations Research Society of America. A Policy Decision Modeling of the Costs and Outputs of Medical Education in West Virginia. @

Membership in Professional and Scientific Societies:

National Societies:

Association for Health Services Research, 1986 to present
International Health Economics Association, 2001 to present
International Society for Pharmacoeconomics and Outcomes Research, 1995 to present
International Society for Quality of Life Research, 1995 to present
Society for Medical Decision Making, 1986 to present

Local Societies: None

Scientific Committees:

Invited reviewer, Centers for Disease Control and Prevention, Office of Noncommunicable Diseases, Injury, and Environmental Health, National Center for Injury Prevention Special Emphasis Panel FOA RFA-CE-13-002: Research Grants for Preventing Violence and Violence Related Injury, Atlanta, Georgia, May 15-16, 2013.

Invited reviewer, Centers for Disease Control and Prevention, National Center for Injury Prevention Special Emphasis Panel (ZCE1 JXS (02)), R49 Grants for Injury Control Research Centers, Atlanta, Georgia, February 21-22, 2012.

Advisor, Comparative Effectiveness Research Advisory Panel, Pfizer Inc., New York, New York, December 2, 2010.

One-to-One Mentoring, 31st Annual Meeting of the Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.

Speaker and participant, Pharmacoeconomic Outcomes in AD Clinical Trials for Dimebon: an Advisory Panel. Co-sponsored by the Alzheimer's Drug Discovery Foundation, Medivation and Pfizer, Inc., New York, New York, June 12, 2009.

Invited reviewer, Clinical Trials Review Committee, 2009/10 CLTR (OA), National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, Md., July 30, 2009.

Consultant, Diabetes Technical Modelling Meeting, Eli Lilly and Company, London, England, November 18-19, 2008.

Invited reviewer, (S3) for the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel ZDK1 GRB-B J1 1 (in response to PA-07-205 Research on the Economics of Diet), the National Institutes of Health, Bethesda, Md., December 7, 2007.

Moderator, Amgen AMG 317 Global Health Economics Advisory Board Meeting, Washington, D.C., September 29-30, 2007.

Moderator, Amgen AMG 108 Joint GHE/DEV Advisory Board, Washington, D.C., September 15, 2007.

Invited reviewer, (P1) for R01 HL085327-01A1, Clinical Trials Review Committee, 2007/05 CLTR (MA) (S), National Heart, Lung, and Blood Institute, the National Institutes of Health, Baltimore, Md., February 26-27, 2007.

Invited reviewer, Scientific Review of the Diabetes Systems Model, Centers for Disease Control and Prevention, Division of Diabetes Translation, Decatur, Georgia, February 19-20, 2007.

One-to-One Mentoring, 28th Annual Meeting of the Society for Medical Decision Making, Boston, Massachusetts, October 14-18, 2006.

Consultant, Longitudinal Assessment of Bariatric Surgery (LABS) consortium Data Safety and Monitoring Board, reviewer of the Health Economics substudy for LABS-3, the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, August 18, 2006. Re-review, January 19, 2007.

Consultant, GSK Global Clinical Outcomes Trials Advisory Board, Philadelphia, PA, June 28-29, 2006.

Member, International Society of Pharmaceutical Outcomes Research Economic Data Transferability Task Force, January 2006 to January 2009.

Moderator, Amgen Multinational Studies Advisory Board, San Francisco, California, December 16, 2005.

Invited reviewer, (S1) for R03 DK074408-01, Review Branch, NIDDK Review Panel 2006/01 ZDK1 GRB-8 (J1) (1), Small Clinical Grants in Digestive

Diseases, Nutrition, and Obesity (in response to PAR-04-082), the National Institutes of Health, Bethesda, Md., December 7, 2005.

Consultant, Improving Survival in COPD - Assessing the Value of Life-saving Therapy, GlaxoSmithKline Advisory Board, Rome, Italy, November 3-4, 2005.

Consultant, FIELD Trial Expert Group Meeting on FIELD Study Quality of Life & Economic Evaluation, Barcelona, Spain, July 14-15, 2005.

Invited reviewer, (P1) for R01 DK070196-01A1, (S1) for R01 DK072466-01 , (S2) for R01 DK072493-01, Review Branch, NIDDK Special Emphasis Panel, 2005/05 ZDK1 GRB-N (M2) Ancillary Studies to Obesity Related Clinical Trials (in response to RFA DK-03-022), the National Institutes of Health, Rockville, Md., March 22, 2005.

Chair, Economics Committee for "Studies to Treat or Prevent Pediatric Type 2 Diabetes (STOPP-T2D)" Prevention Study, National Institute of Diabetes and Digestive and Kidney Disease, the National Institutes of Health, July 2004 to present.

Member, International Society of Pharmaceutical Outcomes Research
Randomized Clinical Trial-Cost Effectiveness Analysis Task Force,
January 2004 to September 2005.

Invited participant, Economic Analyses Conducted Alongside Multinational Clinical Trials Round Table, Duke Clinical Research Institute, Durham, N.C., August 28, 2003.

Invited reviewer (primary) for RO1 HG002941-01, Center for Scientific Review, Center for Scientific Review Special Emphasis Panel, ZRG1 ELSI-2 (90) Ethical, Legal, and Social Implications of Genetics, the National Institutes of Health, Washington, D.C., March 21, 2003.

Invited reviewer (primary) for RO1 GM068700-01, Center for Scientific Review, Center for Scientific Review Special Emphasis Panel, ZRG1 PHRA (61) Adverse Drug Reactions, the National Institutes of Health, Washington, D.C., February 28, 2003.

One-to-One Mentoring, 24th Annual Meeting of the Society for Medical Decision Making, Baltimore, Maryland, California, October 19-23, 2002.

Invited Reviewer (Clinical Economics Subcommittee, primary; Duke University

U10 Application, secondary), 2U10 CA31946 22, NCI-H Review Panel/
Site Visit of Cancer and Leukemia Group B Chairman=s Grant, Leukemia
Correlative Sciences Grant and additional Institutional Grants,
Competitive Renewal Application, National Cancer Institute, National
Institutes of Health Durham, North Carolina, October 14-16, 2002.

One-to-One Mentoring, 23rd Annual Meeting of the Society for Medical Decision
Making, San Diego, California, October 21-24, 2001.

Consultant, Second International Ketek Health Economics Advisory Board
Meeting, Las Vegas, Nevada, June 9, 2001.

Invited Observer, A Economic Evaluation of Vaccination Against Viral
Hepatitis,@ Viral Hepatitis Prevention Board, Istanbul, Turkey, October
11-13, 2000.

Temporary Adviser, Expert Review of Methods for Estimating Hepatitis B
Disease Burden, World Health Organization, Geneva, Switzerland, May
30-31, 2000.

Co-Chair, Economics Committee for the "Action for Health in Diabetes
(LookAHEAD) Study,@ National Institute of Diabetes and Digestive and
Kidney Disease, the National Institutes of Health, January 2000 to present.

Study Group/Executive Committee for Cooperative Study #430 A Reducing the
Efficacy-Effectiveness Gap in Bipolar Disorder,@ Department of Veterans
Affairs, Maryland Health Care System, November 1997 to 2004.

Local Scientific Committees: None

Editorial Positions:

Reviewer, Journal of the American Medical Association, 1992 to present
Reviewer, The Joint Commission Journal on Quality Improvement, 2001 to present
Reviewer, Health Economics, 1998 to present
Reviewer, Medical Care, 1997 to present
Reviewer, Medical Decision Making, 1998 to present
Reviewer, Journal of Clinical Oncology, 2001 to present
Reviewer, Annals of Internal Medicine, 1997 to present

Academic Committees at the University of Pennsylvania and Affiliated Hospitals: None

Major Teaching and Clinical Responsibilities at the University of Pennsylvania and Affiliated Hospitals:

1. Cost-Benefit and Cost-Effectiveness Analysis (HCMG901/301), co-teaching, 1986 to present.
2. Clinical Economics and Clinical Decision Making (EP550), co-teaching, 1986 to present.
3. Faculty advisor, Masters of Science in Clinical Epidemiology, Center for Clinical Epidemiology and Biostatistics, Fall 1998 to present.
4. Faculty co-advisor, Masters of Science in Clinical Epidemiology, Center for Clinical Epidemiology and Biostatistics, Fall 1986 to Spring 1998.
5. Economic Evaluation of Medical Therapies (EP816), co-teaching, Summer 2007.
6. Comparative Understanding of Health Policy and Management: Economic Evaluation of Medical Therapies. Penn-Kyung Hee Collaborative 2007 Summer Program in Global Governance & East Asian Civilization, co-teaching, Seoul, Korea, Summer 2007.
7. Pharmacoeconomics (taught at the U.S. Food and Drug Administration), Course Director and Lecturer, Fall 2010.
8. Pharmacoeconomics (taught at the U.S. Food and Drug Administration), Course Director and Lecturer, Spring 2012.
9. Pharmacoeconomics (taught at the U.S. Food and Drug Administration), Course Director and Lecturer, Fall 2013.
10. Pharmacoeconomics (taught at the U.S. Food and Drug Administration), Course Director and Lecturer, Spring 2015.

Lectures by Invitation: (Last ten years)

March 12, 2012

"Introduction to Economic Analysis," Pharmacoeconomics. U.S. Food and Drug Administration, Silver Spring, Maryland.

- March 19, 2012 "Cost-Effectiveness Analysis," PharmacoEconomics. U.S. Food and Drug Administration, Silver Spring, Maryland.
- March 26, 2012 "Practical Costing" and "Discounting in Economic Evaluation," PharmacoEconomics. U.S. Food and Drug Administration, Silver Spring, Maryland.
- April 16, 2012 "Preferences Assessment," PharmacoEconomics. U.S. Food and Drug Administration, Silver Spring, Maryland.
- April 23, 2012 "Sampling Uncertainty and Patient-Level Cost-Effectiveness Analysis," PharmacoEconomics. U.S. Food and Drug Administration, Silver Spring, Maryland.
- June 3, 2012 2 lectures: "Designing Economic Evaluations in Clinical Trials" and "Evaluating Sampling Uncertainty in Cost-Effectiveness Analysis," Short Course, Statistical Considerations in Health Economic Evaluations, 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington D.C.
- June 3, 2012 2 lectures: "Sampling Uncertainty and Patient-Level Cost-Effectiveness Analysis" and "Sample Size and Power for the Comparison of Cost and Effect," Short Course, Applications of Statistical Considerations in Health Economic Evaluations, 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington D.C.
- October 11, 2012 "Cost Effectiveness Analysis Within an RCT," Pelvic Floor Disorder's Network Steering Committee Meeting, Philadelphia, Pennsylvania.
- May 19, 2013 2 lectures: "Designing Economic Evaluations in Clinical Trials" and "Evaluating Sampling Uncertainty in Cost-Effectiveness Analysis," Short Course, Statistical Considerations in Health Economic Evaluations, 18th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana.
- June 24, 2013 "Impact of a Lifestyle Intervention on Health Care Costs and Utilization," CT-SY24 Symposium, Primary Result of the Look AHEAD Randomized Controlled Trial of a Lifestyle Intervention in Overweight and Obese Individuals with Type 2 Diabetes, 73rd

scientific sessions, American Diabetes Association, Chicago, Illinois.

- July 19, 2013 "Cost-Effectiveness Analysis Within an RCT," Value Institute Lunch Seminar, Christiana Care Health System, Christiana, DE. (<http://www.uphs.upenn.edu/dgimhsr/documents/CEAwithinRCT.pdf>)
- October 30-November 1, 2013 3 lectures: "Designing Economic Evaluations in Clinical Trials," "Analyzing Treatment Costs in Clinical Trials," and "Sampling Uncertainty, Hard Cases, and Sample Size." Short Course, Economic Evaluation in Clinical Trials, University of Glasgow, Glasgow, Scotland.
- November 22, 2013 "Introduction to Pharmacoeconomics, 6th Medication Safety Conference 2013, Abu Dhabi, UAE. (<http://www.uphs.upenn.edu/dgimhsr/documents/pharmacoeconomics.abudhabi.pdf>)
- November 24, 2013 "Risk Sharing and Pharmacoeconomic Modeling, 6th Medication Safety Conference 2013, Abu Dhabi, UAE. (<http://www.uphs.upenn.edu/dgimhsr/documents/pharmacoeconomicmodeling.abudhabi.pdf>)
- August 22, 2014 Cost-Effectiveness Analysis. Health Economics Introductory Workshop, Leonard Davis Institute of Health Economics, Philadelphia, PA. (<http://www.uphs.upenn.edu/dgimhsr/janssenpharmacoeconomics.htm>)
- November 5 -November 6, 2014 3 lectures: "Designing Economic Evaluations in Clinical Trials," "Analyzing Treatment Costs in Clinical Trials," and "Sampling Uncertainty, Hard Cases, and Sample Size." Short Course, Economic Evaluation in Clinical Trials, University of Glasgow, Glasgow, Scotland.
- April 8, 2015 Cost-Effectiveness Analysis. Invited lecture in EPID 640. Advanced Topics in Epidemiology, University of Pennsylvania, Philadelphia, PA. (<http://www.uphs.upenn.edu/dgimhsr/documents/advancedepi.sp2015.pdf>)
- May 19, 2015 Identifying an Appropriate Link and Family for Generalized Linear Models, ISPOR 20th Annual International Meeting, Philadelphia, PA. (<http://www.uphs.upenn.edu/dgimhsr/GammaLogornot.htm>)

- December 14, 2015 Comparative Effectiveness and Cost-Effectiveness Analyses Frequently Agree on Value. Special Lecture, Department of Pharmacology, Siriraj Hospital, Mahidol University, Bangkok, Thailand. (http://www.uphs.upenn.edu/dgimhsr/documents/CER_CEA.siriraj.121415.pdf)
- April 5, 2016 Economics and Finances of Programs for Sleep Disorders. Inaugural Sleep Health and Wellness Forum, Institute for Health and Productivity Management, University of Pennsylvania, Philadelphia, PA. (http://www.uphs.upenn.edu/dgimhsr/documents/glick.sleep_wellness.040516.pdf)
- April 13, 2016 Cost Effectiveness Analysis, Invited lecture in Epid 640, Advanced Topics in Clinical Epidemiology, University of Pennsylvania, PA. (<http://www.uphs.upenn.edu/dgimhsr/documents/advancedepi.sp2016.pdf>)
- May 15, 2016 Economic Evaluation in Clinical Trials, Annual Pre-Conference Workshop, Society for Clinical Trials, Montreal, Ca. (<http://www.uphs.upenn.edu/dgimhsr/documents/SCT.econanalintrials.pdf>)
- September 4, 2016 2 lectures: "Designing Economic Evaluations in Clinical Trials" and "Evaluating Patient Level Costs," Short Course, Statistical Considerations in Health Economic Evaluations, ISPOR 7th Annual Asia-Pacific Conference, Singapore.
- October 5, 2016 Pharmacoeconomics. LDI Health Economics and Management Workshop, Leonard Davis Institute of Health Economics, Philadelphia, PA.
- May 12, 2017 Sample Size and Power, World Well-Being Project, University of Pennsylvania, Philadelphia, PA.
- July 13, 2017 Sample Size and Power for Cost-effectiveness Analysis. NRG Oncology July 2017 Semiannual Meeting, Philadelphia, PA.
- December 2, 2020 Designing Economic Evaluations in Clinical Trials. ISPOR Australia Chapter Webinar. Economic Evaluation in Clinical Trials, Australia.

Organizing Roles in Scientific Meetings:

October 2010	Course Director, Short Course PM5, Economic Assessment in Clinical Trials, 32nd Annual Meeting of the Society for Medical Decision Making, Toronto, Canada
October 2009	Course Director, Short Course PM7, Economic Assessment in Clinical Trials, 31st Annual Meeting of the Society for Medical Decision Making, Hollywood, California
October 2008	Course Director, Short Course W02, Economic Assessment in Clinical Trials, 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia, Pennsylvania
October 2007	Course Director, Short Course 16, Economic Assessment in Clinical Trials, 29th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, Pennsylvania
October 2006	Course Director, Short Course 8, Economic Assessment in Clinical Trials, 28th Annual Meeting of the Society for Medical Decision Making, Boston, Massachusetts
October 2005	Course Director, Short Course 15, Economic Assessment in Clinical Trials, 27th Annual Meeting of the Society for Medical Decision Making, San Francisco, California
October 2005	Course Director, Short Course 8, 2x2 and Stratum-Specific Likelihood Ratio Approaches to Interpreting Diagnostic Tests, 27th Annual Meeting of the Society for Medical Decision Making, San Francisco, California.
October 2004	Course Director, Short Course 10, Prospective Economic Evaluation of Clinical Trials: Methods and Analysis, 26th Annual Meeting of the Society for Medical Decision Making, Atlanta, Georgia
May 2004	Panel Chairman and Moderator, Issues Panel 2, Stratified Cost-effectiveness Analysis: The Risks and Rewards of Looking at Subgroups, ISPOR 9th annual international meeting, Arlington, Virginia.
October 2003	Course Director, Short Course 6, Prospective Economic Evaluation of Clinical Trials: Methods and Analysis, 25th Annual Meeting of the Society for Medical Decision Making, Chicago, Illinois

- June 2003 Seminar Director, Seminar in Health Services Research Methods: Analysis of Costs Using Patient Level Data from Randomized Designs, 20th Annual Research Meeting, Academy Health, Nashville, Tennessee.
- May 2003 Issues Panels and Contributed Workshop Review Committee Chair, Short Course Director, 8th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia
- October 2002 Course Director, Short Course 7, Prospective Economic Evaluation of Clinical Trials: Methods and Analysis, 24th Annual Meeting of the Society for Medical Decision Making, Baltimore, Maryland
- June 2002 Session Chair, Concurrent Session, CEA: New Methodologic Approaches, Annual Research Meeting, Academy of Health Services Research and Health Policy, Washington, D.C.
- October 2001 Session Co-Chair, Pharmacoeconomics, 23rd Annual Meeting of the Society for Medical Decision Making, San Diego, CA.
- October 2001 Course Director, Short Course 3, Prospective Economic Evaluation of Clinical Trials: Methods and Analysis, 23rd Annual Meeting of the Society for Medical Decision Making, San Diego, CA.
- June 2001 Co-Chair, 2-day postconference workshop, Implementing Technology Assessment: Training for Those Who Practice Technology Assessment or Train Others, International Society of Technology Assessment in Health Care, Plymouth Meeting, PA.
- February 2001 Program chair and Session Chair, Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association, London, England.
- November 1999 Program chair and Session Chair, Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association, Orlando, Fl.
- June 1999 Session Chair, Statistical Issues in Health Economics, 35th Annual Meeting of the Drug Information Association, Baltimore, MD.
- March 1999 Co-Chair, 3-day Technology Assessment Workshop, Siriraj Hospital, Bangkok, Thailand.

- February 1999 Program co-chair, Clinical Economics Workshop at XVIth annual meeting of the International Clinical Epidemiology Network, Bangkok, Thailand.
- November 1998 Program co-chair and Session Chair, Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association, New Orleans, LA.
- February 1998 Program co-chair, Clinical economics workshop at XVth annual meeting of the International Clinical Epidemiology Network, Queretaro, Mexico.
- November 1997 Program chair and Session Chair, Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association, Hilton Head, SC.
- November, 1996 Session chair, Cost Effectiveness Analysis: Measures and Methods in Clinical Trials, Drug Information Association, New Orleans, LA.
- October 1996 Program co-chair, Evidence to Action: Developing and Implementing Guidelines for Cost-Effective Care, International Clinical Epidemiology Network, Cebu, Philippines.

Bibliography:

Researched Publications, peer reviewed

1. **Glick HA**, Feuer MJ. Employer-Sponsored Training and the Governance of Specific Human Capital Investments. *Quarterly Review of Economics and Business*. 1984;24:91-104.
2. Feuer M, **Glick H**, Desai A. Is Firm-Sponsored Education Viable? *Journal of Economic Behavior and Organization*. 1987;8:121-136.
3. Lee HL, Pierskalla WP, Kisick WL, Levy JH, **Glick HA**, Bloom BS. Policy Decision Modeling of the Costs and Outputs of Education In Medical Schools. *Operations Research*. 1987;35:667-683.
4. Eisenberg JM, Koffer H, **Glick HA**, Connell ML, Loss LE, Talbot GH, Shusterman NH, Strom BL. What is the cost of nephrotoxicity associated with aminoglycosides? *Annals of Internal Medicine*. 1987;107:900-9. Reprinted in *Supplement to Urology*, 1988;XXXI:45-

56.

5. Eisenberg JM, Schwartz JS, McCaslin FC, Kaufman R, **Glick H**, Kroch E, Substituting diagnostic services. New tests only partly replace older ones. *Journal of the American Medical Association*. 1989;262:1196-1200.
6. Schulman KA, Kinosian B, Jacobson TA, **Glick H**, Willian MK, Koffer H, Eisenberg JM. Reducing High Blood Cholesterol with Drugs: Cost-Effectiveness of Pharmacologic Management. *Journal of the American Medical Association*. 1990;264:3025-3033. Reprinted in *Journal of the American Medical Association (Korean Edition)*. 1991;6:29-32.
7. Schulman KA, **Glick H**, Rubin H, Eisenberg JM. Cost-Effectiveness of HA-1A Monoclonal Antibody for Gram Negative Sepsis: Economic Assessment of a New Therapeutic Agent. *Journal of the American Medical Association*. 1991;266:3466-3471.
8. **Glick HA**, Eisenberg JM, Koffer H, Loss LE, Connell ML. Savings from Faster Return to Nursing Homes for Patients Hospitalized for Infection. *Journal of Research in Pharmaceutical Economics*. 1991;3:41-70.
9. Schulman KA, Lynn L, Glick HA, Eisenberg JM. Cost Effectiveness of Low-Dose Zidovudine for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection. *Annals of Internal Medicine*. 1991;114:798-802.
10. Okubo I, **Glick H**, Frumkin H, Eisenberg JM. Cost-Effectiveness Analysis of Mass Screening for Breast Cancer in Japan. *Cancer*. 1991;67:2021-2029.
11. **Glick H**, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A Model for Evaluating the Cost-Effectiveness of Cholesterol-Lowering Treatment. *International Journal of Technology Assessment in Health Care*. 1992;8:719-734.
12. Shulkin DJ, Kinosian B, **Glick H**, Glen-Puschett C, Daly J, Eisenberg JM. The Economic Impact of Infections: An Analysis of Hospital Costs and Charges in Surgical Oncology Patients. *Archives of Surgery*. 1993;128:449-452.
13. Eisenberg JM, **Glick HA**, Buzby GP, Kinosian B, Williford WO. Does Perioperative Total Parenteral Nutrition Reduce Medical Care Costs? *Journal of Parenteral and Enteral Nutrition*. 1993;17:201-209.
14. Shulkin DJ, Kinosian B, **Glick H**, Sirio C, Glen-Puschett C, Daly J. Explaining Cost Variations in Clinical Trials Using Severity of Illness Measures. *Clinical Performance and Quality Management*. 1993;1:134-137.

15. **Glick H**, Brainsky A, McDonald RC, Javitt JC. The Cost of Illness in Glaucoma in the United States: 1988. *Chibret International Journal of Ophthalmology*. 1994;10:6-12.
16. Shimbo T, **Glick H**, Eisenberg JM. Cost-Effectiveness Analysis of Strategies for Colorectal Cancer Screening in Japan. *International Journal of Technology Assessment in Health Care*. 1994;10:359-375.
17. Solomon NA, **Glick HA**, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. *Stroke*. 1994;25:1721-1725.
18. Kinoshian B, **Glick H**, Garland G. Cholesterol and Coronary Heart Disease: Predicting Risks By Levels and Ratios. *Annals of Internal Medicine*. 1994;121:641-647. Abstracted in *Report on Medical Guidelines & Outcomes Research*. 1994;5:5-6.
19. Lee JH, **Glick HA**, Kinoshian B, Schulman KA. An Interactive Computer Model for Formulary Management Using Cost-Effectiveness Analysis. *M.D. Computing*. 1995;12:59-65.
20. Schulman KA, **Glick HA**. Economic Evaluation of High Dose Chemotherapy and Bone Marrow Transplantation for Patients with Breast Cancer of Stage II or Stage IIIA with More Than 10 Positive Lymph Nodes at Surgical Excision. *Monographs of the National Cancer Institute*. 1995;19:45-50.
21. King JT Jr, **Glick H**, Mason TJ, Flamm ES. Elective Surgery for Asymptomatic, Unruptured, Intracranial Aneurysms: A Cost-Effectiveness Analysis. *Journal of Neurosurgery*. 1995;83:403-412.
22. Kinoshian B, **Glick H**, Preiss L, Puder KL. Cholesterol and Coronary Heart Disease: Predicting Risks in Men by Changes in Levels and Ratios. *Journal of Investigative Medicine*. 1995;43:443-50.
23. **Glick H**, Cook J, Kinoshian B, Pitt B, Bourassa MG, Pouleur H, Gerth W. Costs and Effects of Enalapril Therapy in Patients with Symptomatic Heart Failure: An Economic Analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. *Journal of Cardiac Failure*. 1995;1:371-80.
24. Awasthi S, **Glick HA**, Fletcher RH. Effect of Cooking Fuels on Respiratory Diseases in Preschool Children in Lucknow, India. *American Journal of Tropical Medicine and Hygiene*. 1996;55:48-51.
25. Awasthi S, Pande VK, **Glick H**. Under Fives Mortality in the Urban Slums of Lucknow. *Indian Journal of Pediatrics*. 1996;63:363-68.

26. Awasthi S, **Glick HA**, Fletcher RH, Ahmed N. Ambient Air Pollution and Respiratory Symptoms Complex in Preschool Children. *Indian Journal of Medical Research*. 1996;104:257-62.
27. Schulman KA, Buxton M, **Glick H**, Sculpher M, Guzman G, Kong J, Backhouse M, Mauskopf J, Bell L, Eisenberg JM, the First Investigators. Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation. *International Journal of Technology Assessment in Health Care*. 1996;12:698-713.
28. Brainsky A, **Glick H**, Lydick E, Epstein R, Fox KM, Hawkes W, Kashner M, Zimmerman SI, Magaziner J. The Economic Cost of Hip Fractures in Community-Dwelling Elderly: A Prospective Study. *Journal of the American Geriatrics Society*. 1997;45:281-87.
29. Willke RJ, **Glick HA**, McCarron TJ, Erder MH, Althof SE, Linet OI. Quality of Life Effects of Alprostadil Therapy for Erectile Dysfunction. *Journal of Urology*. 1997;157:2124-2128.
30. Brainsky A, Fletcher RH, **Glick HA**, Lancken PN, Williams SV, Kundel HL. Routine Portable Chest Radiographs in the Medical Intensive Care Unit: Effects and Costs. *Critical Care Medicine*. 1997;25:801-805.
31. Polsky D, **Glick HA**, Willke R, Schulman K. Confidence Intervals for Cost effectiveness Ratios: A Comparison of Four Methods. *Health Economics*. 1997;6:243-252.
32. **Glick HA**, McCarron TJ, Althof SE, Corty EW, Willke RJ. Construction of Scales for the Center for Marital and Sexual Health (CMASH) Sexual Functioning Questionnaire. *Journal of Sex and Marital Therapy*. 1997;23:103-117.
33. **Glick H**, Willke R, Polsky D, Llana T, Alves WM, Kassell N, Schulman K. Economic Analysis of Tirilazad Mesylate for Aneurysmal Subarachnoid Hemorrhage: Economic Evaluation of a Phase III Clinical Trial in Europe and Australia. *International Journal of Technology Assessment in Health Care*. 1998;14:145-160.
34. **Glick HA**, Polsky D, Willke RJ, Alves WM, Kassell N, Schulman K. Comparison of the Use of Medical Resources and Outcomes in the Treatment of Aneurysmal Subarachnoid Hemorrhage between Canada and the United States. *Stroke*. 1998;29:351-358.
35. Schulman KA, Dorsainvil D, Yabroff KR, DiCesare J, Felser J, Eisenberg JM, **Glick HA**. Prospective Economic Evaluation Accompanying a Trial of GM-CSF/IL-3 in Patients Undergoing Autologous Bone-Marrow Transplantation for Hodgkins and Non-Hodgkins Lymphoma. *Bone Marrow Transplantation*. 1998;21:607-614.
36. **Glick HA**, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. Empirical

- Criteria for the Selection of Quality-of-Life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation. *International Journal of Technology Assessment in Health Care*. 1998;14:419-430.
37. Willke RJ, **Glick HA**, Polsky D, Schulman K. Estimating Country-Specific Cost-Effectiveness from Multinational Clinical Trials. *Health Economics*. 1998;7:481-93.
 38. Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, Harris A, Lucioni C, Gisbert R, Llana T, Tom E, Bloom B, Willke R, **Glick H**. Resource Costing for Multinational Neurologic Clinical Trials: Methodology and Results. *Health Economics*. 1998;7:629-38.
 39. Cook JR, **Glick HA**, Gerth W, Kinosian B, Lostis JB. The Cost and Cardioprotective Effects of Enalapril in Hypertensive Patients with Left Ventricular Dysfunction. *American Journal of Hypertension*. 1998;11:1433-1441.
 40. Willke RJ, Yen WM, Parkerson GR Jr, Linet OI, Erder MH, **Glick HA**. Quality of Life Effects of Alprostadil Therapy for Erectile Dysfunction: Results of a Trial in Europe and South Africa. *International Journal of Impotence Research*. 1998;10:239-46.
 41. Fendrick AM, Lee JH, LaBarge C, **Glick H**. Clinical and Economic Impact of a Combination Haemophilus Influenzae and Hepatitis B Virus Vaccine. *Archives of Pediatrics & Adolescent Medicine*. 1999;153:126-36.
 42. Schulman KA, Yabroff KR, Kong J, Gold KF, Rubenstein LE, Epstein AJ, **Glick HA**. claims data approach to defining an episode of care. *Health Services Research*. 1999 34:603-21. (Reprinted in *Pharmacoepidemiology and Drug Safety*, 2001;10:417-27.)
 43. **Glick HA**, Polsky D, Willke RJ, Schulman KA. A Comparison of Preference Assessment Instruments Used in a Clinical Trial: Responses to the Visual Analog Scale from the EuroQol EQ-5D and the Health Utilities Index. *Medical Decision Making*. 1999;19:265-75.
 44. Weinfurt KP, Willke R, **Glick H**, Schulman KA. Toward a Composite Scoring Solution for the Neurobehavioral Functioning Inventory. *Quality of Life Research*. 1999;8:17-24
 45. Mehta SS, Suzuki S, **Glick HA**, Schulman KA. Determining an Episode of Care Using Claims Data: Diabetic Foot Ulcer. *Diabetes Care*. 1999;22:1110-1115.
 46. Weinfurt KP, Willke R, **Glick H**, Freimuth WW, Schulman KA. The Relationship Between CD4 Count, Viral Burden, and Quality of Life Over Time in HIV-1 Infected Patients. *Medical Care*. 2000;38:404-410.

47. Kinoshian B, Stallard E, Lee J, Woodbury MA, Zbrozek AS, **Glick HA**. Predicting 10-Year Care Requirements for Elders with Suspected Alzheimer=s Disease. *Journal of the American Geriatrics Society*. 2000;48:631-8.
48. Bauer MS, Vojta C, Kinoshian B, Altshuler L, **Glick H**. The Internal State Scale: Replication of its Discriminating Abilities in a Multisite, Public-Sector Sample. *Bipolar Disorders*. 2000;2:340-6.
49. Polsky D, Willke R, Scott K, Schulman K, **Glick HA**. A Comparison of Scoring Weights for the EuroQol Derived from Patients and the General Public. *Health Economics*. 2001;10:27-37.
50. Li ZM, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Piel AM, Crouch CW, Hafkin B, **Glick HA**. Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin-Resistant *Staphylococcus* Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial. *Pharmacotherapy*. 2001; 21:263-74.
51. Vojta C, Kinoshian B, **Glick H**, Altshuler L, Bauer MS. Self-Reported Quality of Life Across Mood States in Bipolar Disorder. *Comprehensive Psychiatry*. 2001;42:190-5.
52. Patel AB, Williams SV, Frumkin H, Kondawar VK, **Glick H**, Ganju AK. Blood Lead in Children and its Determinants in Nagpur, India. *International Journal of Occupational & Environmental Health*. 2001;7:119-26.
53. Polsky D, Bundorf MK, **Glick HA**, Scalzi C, Kinoshian BP. Is the Nurse Responsible for Resource Use in Home Health Care? *Journal of Clinical Outcomes Management*. 2001;8:29-35.
54. Polsky D, Onesirosan P, Bauer M, **Glick HA**. Duration of Therapy and Health Care Costs of Fluoxetine, Paroxetine, and Sertraline in Six Health Plans. *J Clin Psychiatry*. 2002;63:156-64.
55. **Glick HA**, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure. *Cardiovascular Drugs and Therapy*. 2002;16:53-9.
56. Lee JH, **Glick HA**, Hayman JA, Solin LJ. Decision-Analytic Model and Cost-Effectiveness Evaluation of Postmastectomy Radiation Therapy for High-Risk Premenopausal Breast Cancer. *Journal of Clinical Oncology*. 2002;20:2713-25.
57. Siderowf A, Ravina B, **Glick HA**. Preference-Based Quality-of-Life in Patients with Parkinson's Disease. *Neurology*. 2002;59:103-8.

58. Willke RJ, **Glick HA**, Li Z, Rittenhouse BE. Effects of Linezolid on Hospital Length of Stay Compared with Vancomycin in Treatment of Methicillin-Resistant Staphylococcus Infections: An Application of Multivariate Survival Analysis. *Int J Tech Asses in Health Care*. 2002;18:540-54.
59. Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, **Glick HA**, Hadley J, Schulman KA. An Economic Evaluation of Breast Cancer Treatment: Considering the Value of Patient Choice. *Journal of Clinical Oncology*. 2003;21:1139-46.
60. Cook JR, Drummond M, **Glick H**, Heyse JF. Assessing the Appropriateness of Combining Economic Data from Multinational Clinical Trials. *Statistics in Medicine*. 2003;22:1955-76.
61. **Glick HA**, Orzol SM, Tooley JF, Polsky D, Mauskopf JM. Design and Analysis of Unit Cost Estimation Studies: How Many Hospital Diagnoses? How Many Countries? *Health Economics*. 2003;12:517-27.
62. Pillai RK, Williams SV, **Glick H**, Polsky D, Berlin JA, Lowe RA. Factors Affecting Decision to Seek Treatment for Sick Children in Kerala, India. *Social Science and Medicine*. 2003;57:783-90.
63. Natarajan S, **Glick H**, Criqui M, Horowitz D, Lipsitz S, Kinosian B. Cholesterol Measures to Identify and Treat Individuals at Risk for Coronary Heart Disease. *American Journal of Preventive Medicine*. 2003;25:50-7.
64. Schulman KA, Stadtmauer EA, Reed SD, **Glick HA**, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH. Economic Analysis of Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy Plus Autologous Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer. *Bone Marrow Transplantation*. 31:2003:205-10.
65. Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, **Glick H**, Stanley CA. Newborn Screening by Tandem Mass Spectrometry for Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD): A Cost-Effectiveness Analysis. *Pediatrics*. 2003;112:1005-15.
66. **Glick H**, McBride L, Bauer MS. A Manic-Depressive Symptom Self-Report in Optical Scannable Format. *Bipolar Disorders*. 2003;5:366-9.
67. **Glick HA**, Kinosian B, McBride L, Williford WO, Bauer MS for the CSP #430 Study Team. Clinical Nurse Specialist Care Managers' Time Commitments in a Disease-management Program for Bipolar Disorder. *Bipolar Disorders*. 2004;6:452-9.
68. Tsai AG, **Glick HA**, Shera D, Stern L, Samaha FF. Cost-Effectiveness of a Low-

- Carbohydrate and a Low-Calorie Diet in Severe Obesity. *Obesity Research*. 2005;13:1834-40.
69. Glaser R, **Glick HA**, Herrmann HC, Kimmel SE. The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis. *Journal of the American College of Cardiology*. 2006;47:529-37. Letter to the editor and Authors' reply, *Journal of the American College of Cardiology*. 2007;49:276-7.
70. DeWitt EM, **Glick HA**, Albert DA, Joffe MM, Wolfe F. Medicare Coverage of TNF-alpha Inhibitors Influences Prescribing Behavior. *Archives of Internal Medicine*. 2006;166:57-63. DeWitt EM, **Glick HA**, Albert DA, Wolfe F. Reply to Letter to the Editor from Sherrick RC. *Archives of Internal Medicine*. 2006;166:1418.
71. Bauer MS, McBride L, Williford WO, **Glick H**, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M, and Coauthors for the Cooperative Studies Program 430 Study Team. Collaborative Care for Bipolar Disorder, Part I: Intervention and Implementation in a Randomized Effectiveness Trial. *Psychiatric Services*. 2006;57:927-36.
72. Bauer MS, McBride L, Williford WO, **Glick H**, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M, and Coauthors for the Cooperative Studies Program 430 Study Team. Collaborative Care for Bipolar Disorder, Part II: Impact on Clinical Outcome, Function, and Costs. *Psychiatric Services*. 2006;57:937-45.
73. Stein SC, Burnett MG, **Glick HA**. Indications for CT scanning in mild traumatic brain injury: a cost-effectiveness study. *Journal of Trauma*. 2006;61:558-66. Letter to the editor and Authors' reply, *Journal of Trauma*. 2007;62:1314-5.
74. Polsky D, Doshi JA, Bauer MS, **Glick HA**. Clinical Trial-Based Cost-Effectiveness Analyses of Antipsychotics. *Am J Psychiatry*. 2006;163:2047-56.
75. Doshi JA, **Glick HA**, Polsky DP. Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials. *Value in Health*. 2006;9:334-40.
76. Meropol, SB, **Glick HA**, Asch DA. Age-Inconsistency in the American Academy of Pediatrics Guidelines for Acute Otitis Media. *Pediatrics*. 2008;121:657-68.
77. Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, **Glick HA**. Preference-Based Quality of Life in Patients with Alzheimers Disease. *Alzheimer's & Dementia*. 2008; 4:193-202.
78. Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Low DV, **Glick HA**.

- Caregivers' Assessments of Preference-Based Quality of Life in Alzheimers Disease. *Alzheimer's & Dementia*. 2008; 4:203-211.
79. Stein SC, Fabbri A, Servadei F, **Glick HA**. A Critical Comparison of Clinical Decision Instruments for Computed Tomographic Scanning in Mild Closed Traumatic Brain Injury in Adolescents and Adults. *Annals of Emergency Medicine*. 2009;53:180-8.
80. Volpp K, Troxel A, Pauly M, **Glick H**, Puig A, Asch D, Galvin R, Zhu J, Wan, Fei, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J. A Randomized Controlled Trial of Financial Incentives for Smoking Cessation. *New England Journal of Medicine*. 2009;360:699-709.
81. DeWitt EM, Lin L, **Glick HA**, Anstrom KJ, Schulman KA, Reed SD. Pattern and Predictors of Biologics Initiation in Rheumatoid Arthritis: an ARAMIS Cohort Study. *Clinical Therapeutics*. 2009;166:57-63.
82. Briggs A, **Glick H**, Lozano-Ortega G, Spencer M, Calverley P, Jones P, Vestbo J. Is treatment with ICS and LABA cost-effective for COPD? Multinational Economic Analysis of the TORCH Study. *European Respiratory Journal*. 2010;35:532-9.
83. Redmon, JB, Bertoni, A, Connelly S, Feeney P, Glasser S, **Glick H**, Greenway F, Hesson L, Lawlor M, Montez M, Montgomery B. Effect of the Look AHEAD Study Intervention on Medication Use And Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes. *Diabetes Care*. 2010;33:1153-8.
84. Polsky D, **Glick HA**, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-Effectiveness of Extended Buprenorphine-Naloxone Treatment for Opioid-Dependent Youth: Data from a Randomized Trial. *Addiction*. 2010;105:1616-24.
85. Stallard E, Kinosian B, Zbrozek AS, Yashin AI, **Glick HA**, Stern Y. Estimation and Validation of a Multi-Attribute Model of Alzheimer's Disease Progression. *Medical Decision Making*. 2010;30:625-38.
86. Tsai AG, Williamson DF, **Glick HA**. Direct Medical Cost of Overweight and Obesity in the United States: a Quantitative Systematic Review. *Obesity Reviews*. 2011, 12:50-61.
87. **Glick HA**. Sample Size and Power for Cost-Effectiveness Analysis (2): The Effect of Maximum Willingness to Pay. *Pharmacoeconomics*. 2011;29:287-96.
88. Bowles KH, Hanlon AL, **Glick HA**, Naylor MD, O'Connor M Riegel BJ, Shih NW, Weiner MG. Clinical Effectiveness, Access to and Satisfaction with Care using a Telehomecare Substitution Intervention: A Randomized Controlled Trial. *International Journal of Telemedicine and Applications*. 2011;2011:1-13.

89. Margolis DJ, Gupta J, Hoffstad O, Papdopoulos M, **Glick HA**, Thom SR, Mitra N. Lack of Effectiveness of Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcer and the Prevention of Amputation: A Cohort Study. *Diabetes Care*. DOI: 10.2337/dc12-2160.
90. Dewitt EM, Curtis JR, **Glick HA**, Greenberg JD, Anstrom KJ, Kremer JM Reed G, Schulman KA, Reed SD. Comparative Effectiveness of Nonbiologic versus Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. *J Rheumatol*. 2013;40:127-36.
91. Choudhury RA, Murayama KM, Abt PL. **Glick HA**, Naji A, Williams NN, Dumon KR. Roux-en-Y gastric bypass compared with aggressive diet and exercise therapy for morbidly obese patients awaiting renal transplant: a decision analysis. *Surgery for Obesity and Related Diseases*. 2014;10:79-87.
92. Espeland MA, **Glick HA**, Bertoni A, Brancati FL, Bray GA, Clark JM, Curtis JM, Egan C, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Hazuda HP, Hill JO, Hire D, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Kitabchi AE, Knowler WC, Kriska A, Lewis CE, Miller M, Montez MG, Murillo A, Nathan DM, Nyenwe E, Patricio J, Peters AL, Pi-Sunyer X, Pownall H, Redmon JB, Rushing J, Ryan DH, Safford M, Tsai AG, Wadden TA, Wing RR, Yanovski SZ, Zhang P. Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services among Overweight and Obese Adults with Type 2 Diabetes: The Action for Health in Diabetes. *Diabetes Care*. 2014;37:2548-56.
93. Choudhury RA, Murayama KM, Neylan CJ, Savulionyte G, **Glick HA**, Williams NN, Dempsey DT, Dumon KR. Re-Examining the BMI Threshold for Bariatric Surgery in the USA. *J Gastrointest Surg*. 2014;18:2074-9. doi: 10.1007/s11605-014-2653-7.
94. **Glick HA**, McElligott S, Pauly MV, Willke RJ, Berquist H, Doshi J, Fleisher LA, Kinoshian B, Perfetter E, Polsky DE, Schwartz JS. Comparative Effectiveness and Cost-Effectiveness Analyses Frequently Agree on Value. *Health Affairs*. 2015;34:805-11.
95. **Glick HA**, Li P, Harvey PD. The Relationship Between Positive and Negative Syndrome Scale (PANSS) Schizophrenia Scores and Risk for Hospitalization: An Analysis of the Catie Schizophrenia Trial. *Schizophrenia Research*. 2015.
<http://dx.doi.org/10.1016/j.schres.2015.05.021>.
96. Ferguson MO, Long JA, Zhu J, Small DS, Lawson B, **Glick HA**, Schapira JMM. Low Literacy Predicts Misperceptions of Diabetes Control in Patients with Persistently Elevated A1C. *Diabetes Educator*. 2015;41:309-19.

97. Zhang P, Hire D, Espeland MA, Knowler WC, Thomas S, Tsai AG, **Glick HA**, and the Look AHEAD Research Group. Impact of Intensive Lifestyle Intervention on Preference-Based Quality of Life in Type 2 Diabetes: Results from the Look AHEAD Trial. *Obesity*. 2016;24:856-64.
98. Pagani FD, Aaronson KD,.....,Anderson AS, **Glick HA**,....., et al. The NHLBI REVIVE-IT Study: Understanding its Discontinuation in the Context of Current Left Ventricular Assist Device Therapy. *Journal of Heart and Lung Transplantation*. 2016;35:1277-83.
99. Vaughan EM, Johnston CA, Moreno JP, et al. Symptom prevalence differences of depression as measured by BDI and PHQ scales in the Look AHEAD study. *Obesity Science & Practice*. Early access: DEC 2019.
100. Tuteja S, **Glick H**, Matthai W, Nachamkin I, Nathan A, Monono K, Carcuffe C, Maslowski K, Chang G, Kobayashi T, Anwaruddin S, Hirshfeld Jr J, Wilensky R, Herrmann H, Kolansky D, Rader D, Giri J. Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial. *Circulation: Genomic and Precision Medicine*. CIRCCVG/2019/002640R3
101. **Glick HA**, Miyazaki T, Hirano K, Gonzalez E, Jodar L, Gessner BD, Isturiz RE, Arguedas A, Kohno K, Suaya JA. One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. *Clinical Infectious Diseases*. 2021; 73: 283-90.
102. Van Pelt AE, **Glick HA**, Yang W, Rubin D, Feldman M, Kimmel SE. Evaluation of COVID-19 Testing Strategies for Repopulating College and University Campuses: A Decision Tree Analysis. *Journal of Adolescent Health*. 2021; 68: 28-34.
103. Nelson RE, Lautenbach E, Chang N, Joses M, Wilson T, David M, Linkin D, **Glick H**, Doshi JA, Stevens VW. Attributable Cost of Healthcare-Associated Methicillin-Resistant *Staphylococcus aureus* Infection in A Long-Term Care Center. *Clinical Infectious Diseases*. *Clinical Infectious Diseases*. 2021; 72 (Suppl 1): 527-533s.
104. Wang L, Scott Fl Boursi B, Reiss KA, Williams S, Glick H Yang YX. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients with New-Onset Diabetes. *Clinical Gastroenterology and Hepatology*. 2022; 20: 1997-2004.
105. An J, **Glick HA**, Sawyer AM, Arguelles J, Bae CJ, Keenan BT, Kuna ST, Maislin G, Mazzotti DR, Pack AI, Shi JM, Watach AJ, Dennis Hwang D. Association Between Positive Airway Pressure Adherence and Healthcare Costs Among Individuals with Obstructive Sleep Apnea. *Chest*. 2023 Jan 24; S0012-3692(23)00132-0. doi: 10.1016/j.chest.2023.01.025

106. Lawson GM, Abbas F, Jawad AF, Comly R, Khanna M, **Glick H**, Beidas RS, Goldstein J, Brizzolara-Dove S, Wilson T, Rabenau-McDonnell Q, Eiraldi R. A comparison of two group CBT protocols for anxiety in urban schools: Appropriateness, child outcomes, and cost-effectiveness. *Frontiers in Psychiatry*. In Press

Research Publications, non-peer reviewed: None

Abstracts of Unpublished Research: (past three years)

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. Kitz D, Eisenberg JM, **Glick H**. The Clinical Economics of Nutrition Support Services and Antibiotic Medications for the Critically and Terminally Ill Elderly. Chapter in Life-Sustaining Technologies and the Elderly Working Papers, Volume 2: The Technologies, Part 2. Contract report to OTA. July, 1987. Springfield, Virginia: U.S. Department of Commerce, National Technical Information Service.
2. Eisenberg JM, **Glick H**, Koffer H. Assessing the Hidden Cost of Antibiotic Therapy for Hospitalized Patients. *Drug Information Journal*. 1988;22:459-469.
3. Eisenberg JM, **Glick H**, Hillman AL, Baron J, Finkler SA, Hershey JC, Lavizzo-Mourey R, Buzby GP. Measuring The Economic Impact of Perioperative Total Parenteral Nutrition: rinciples and Design. *American Journal of Clinical Nutrition*. 1988;47:382-391.
4. Eisenberg JM, **Glick H**, Koffer H. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. Chapter 24 in *Pharmacoepidemiology*, ed. by B Strom, New York: Churchill Livingstone, 1989, 325-50.
5. Eisenberg JM, Freund D, **Glick H**, Hall J, Halstead S, Labelle R, Clinical economics education in the International Clinical Epidemiology Network. *Journal of Clinical Epidemiology*. 1989;42:689-95.
6. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, **Glick H**, Kinoshian B, Schwartz JS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies [Sounding Board Editorial] *New England Journal of Medicine* 1991;324:1362-1365. (Reprinted in *Journal of Research in Pharmaceutical Economics*, 1992;4:3-13.)
7. Feuer MJ, Desai A, **Glick H**. Firm Financed Education and Specific Human Capital: A Test

- of the Insurance Hypothesis. Chapter 3 in *Market Failure in Training? New Economic Analysis and Evidence on Training of Employed Adults*, ed. by D. Stern and J.M.M. Ritzen, Berlin: Springer-Verlag, 1991, 41-60.
8. **Glick H**, Kington R.: Pharmacoeconomics: Principles and Basic Techniques of Economic Analysis. Chapter in *Drug Epidemiology and Post-Marketing Surveys*, ed. by B Strom and Velo. Plenum Press. 1992, 115-24. Reprinted from *Economic Analysis of Health Care (Text and slides)*. London: Current Medical Literature, 1990.
 9. **Glick H**, Kinosian B, Schulman K. Decision Analytic Modeling: Some Uses in the Evaluation of New Pharmaceuticals. *Drug Information Journal*, 1994;28:691-707.
 10. Eisenberg JM, Schulman KA, **Glick H**, Koffer H. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. Chapter 32 in *Pharmacoeconomics*, Second Edition, ed. by B Strom, New York: John Wiley & Sons, 1994, 469-93.
 11. **Glick H**, Kinosian B. Evaluating the Efficiency of Cholesterol Modification for Coronary Heart Disease with Decision Analytic Models: A Case Study. *Drug Information Journal*, 1995;29:1441-57.
 12. Schulman KA, Yabroff KR, **Glick H**. A Health Services Approach for the Evaluation of Innovative Pharmaceutical and Biotechnology Products. *Drug Information Journal*, 1995;29:1405-14.
 13. **Glick H**. Strategies for Economic Assessment During the development of New Drugs. *Drug Information Journal*, 1995;29:1391-1403.
 14. Schulman KA, **Glick HA**, Yabroff KR, Eisenberg JM. Introduction to Clinical Economics: The Assessment of Cancer Therapies. *Monographs of the National Cancer Institute*, 1995;19:1-9.
 15. Schulman KA, Rubenstein LE, **Glick HA**, Eisenberg JM. Relationships Between Sponsors and Investigators in Pharmacoeconomics and Clinical Research. *Pharmacoeconomics*. 1995;7:206-220.
 16. Schulman KA, **Glick H**, Buxton M, Sculpher M, Backhouse M, et al. The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial. *Controlled Clinical Trials*, 1996;17:304-315.
 17. Mauskopf J, Schulman K, Bell L, **Glick H**. A Strategy for Collecting Pharmacoeconomics Data During Phase II/III Clinical Trials. *Pharmacoeconomics*. 1996;9:264-77. Reprinted in *Economic Evaluation in Health Care*, ed. by G Mallarkey, Auckland, N.Z.: Adis International, 1999, 87-101.

18. Pitt B, **Glick H**. Heart Failure. Chapter 15 in *Cost Effective Diagnosis and Treatment of Coronary Artery Disease*, ed. by J.D. Talley, P.D. Mauldin, E.R. Becker, Baltimore, MD: Williams & Wilkins, 1997, 189-200.
19. Brown M, **Glick HA**, Harrell F, Herndon J, McCabe M, et al. Integrating Economic Analysis into Cancer Clinical Trials: The NCI-ASCO Economics Workbook. *Journal of the National Cancer Institute Monographs No. 24*, 1998;1-28.
20. Criqui MH, Kinosian B, **Glick H**, Deedwania PC, Krauss RM. The American College of Physicians guidelines for screening blood cholesterol levels: a commentary. *American Journal of Medicine*, 1998;105:75S-76S.
21. Schulman KA, **Glick H**, Detsky AS. Introduction to Decision Analysis. Chapter 7 in *Evidence Based Cardiology*, ed. by S Yusuf, J.A. Cairns, A.J. Camm, E.L. Fallen, B.J. Gersh, London: BMJ Books, 1998, pp. 92-111.
22. Kinosian B, **Glick H**. Clinical Trials and External Validity. *Value in Health*. 1998;1:181-85.
23. Boyko WL Jr., **Glick HA**, Shulman KA. ACE Inhibitors in the Management of Congestive Heart Failure: Comparative Economic Data. *American Heart Journal* 1999;137:S115-9.
24. Schulman KA, Ohishi A, Park J, **Glick HA**, Eisenberg JM. Clinical Economics in Clinical Trials: the Measurement of Cost and Outcomes in the Assessment of Clinical Services Through Clinical Trials. *Keio Journal of Medicine* 1999; 48: 1-11.
25. **Glick HA**, Polsky D. Analytic Approaches for the Evaluation of Costs. *Hepatology*. 1999;29:18S-22S.
26. Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, **Glick H**. The Development of Standard Economic Datasets for Use in the Economic Evaluation of Medicines. *Drug Information Journal*, 2000; 34: 1273-1291.
27. Schulman KA, **Glick H**, Polsky D, Eisenberg JM. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. Chapter 35 in *Pharmacoepidemiology*, Third Edition, ed. by BL Strom, New York: John Wiley & Sons, 2000, 573-601.
28. Schulman KA, **Glick HA**, Polsky D, John KR, Eisenberg JM. Pharmacoeconomics. Chapter 4 in *Drug Benefits and Risks*, ed. CJ van Boxtel, B. Santoso, IR Edwards, New York: John Wiley & Sons, 2001, 37-53.
29. **Glick HA**, Briggs AH, Polsky D. Quantifying Stochastic Uncertainty and Presenting the Results of Cost Effectiveness Analyses. *Expert Reviews in Pharmacoeconomics and*

Outcomes Research. 1:2001;89-100.

30. **Glick HA**, Polsky D, Schulman K. Trial-based Economic Evaluations: An Overview of Design and Analysis. Chapter 6 in *Economic Evaluation in Health Care. Merging Theory and Practice*, ed. By Michael Drummond and Alistair McGuire, Oxford: Oxford University Press, 2001, 113-140.
31. Bauer MS, Williford W, Dawson E, Akiskal H, Altshuler L, Fye C, Gelenberg A, **Glick H**, Kinosian B, Sajatovic M. Principles of effectiveness Trials and Their Implementation in VA Cooperative Study #430, AReducing the Efficacy-Effectiveness Gap in Bipolar Disorder.@ *J Affect Disord*. 2002;67:61-78.
32. Beutels P, Edmunds JW, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, **Glick HA**, Mast E, Pechevis M, Van Doorslaer EKA, van Hout BA. Economic Evaluation of Vaccine Programmes. A Consensus Statement Focusing on Viral Hepatitis. (Commentary), *Pharmacoeconomics*. 2002;20:1-7.
33. Li JZ, Willke RJ, Rittenhouse BE, **Glick HA**. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species Infections. *Pharmacotherapy*. 2002;22:45S-54S.
34. Schulman KA, **Glick HA**, Detsky AS. Introduction to Decision Analysis. Chapter in *Evidence Based Cardiology*, Second Edition, ed. by S Yusuf, J.A. Cairns, A.J. Camm, E.L. Fallen, B.J. Gersh, London: BMJ Books, 2003, 56-70.
35. **Glick H**, Cook J. Estimating cost-effectiveness in multinational clinical trials. Chapter 7 in *Statistical Methods for Cost-Effectiveness Research: A Guide to Current Issues and Future Developments*, ed. by AH Briggs. London: Office of Health Economics Research, November, 2003.
36. Hilton ME, Fleming M, **Glick H**, Gutman MA, Lu Y, McKay J, Mclellan AT, Manning W, Meadows J, Mertens JR, Moore C, Mullahy J, Mundt M, Parthasarathy S, Polsky D, Ray GT, Sterling S, Weisner C. Services integration and cost-effectiveness. *Alcoholism: Clinical and Experimental Research*. 2003;27:271-80.
37. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DK, Drummond MF, **Glick HA**, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. *American Heart Journal*. 2005;149:434-43.
38. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, **Glick H**, Liljas B, Petitti D, Reed S. Best Practices for Economic Analysis Alongside Clinical Trials: an

- ISPOR RCT-CEA Task Force Report. *Value in Health*. 2005;8:521-33.
39. Schulman KA, **Glick H**, Polsky D. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. Chapter 41 in *Pharmacoepidemiology*, Fourth Edition, ed. by BL Strom, New York: John Wiley & Sons, 2005, pp 629-52.
 40. Schulman KA, **Glick HA**, Polsky D. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. Chapter 22 in *Textbook of Pharmacoepidemiology*, ed. by BL Strom and SE Kimmel, New York: John Wiley & Sons, 2006, pp 333-44.
 41. Schulman KA, **Glick HA**, Polsky D, John KR. Economic Evaluation of Pharmaceuticals and Clinical Practice. Chapter 4 in *Drug Benefits and Risks*, Revised Second Edition, ed. CJ van Boxtel, B. Santoso, IR Edwards, New York: John Wiley & Sons, 2008, 37-56.
 42. Drummond M, Barbieri M, Cook J, **Glick HA**, Lis J, Malik F, Reed S, Rutten F, Sculpher M, Severens J. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Practices Research Task Force Report. *Value in Health*. 2009;12:409-18.
 43. Polsky D, **Glick HA**. Cost and Cost Analysis in Randomised Trials: Caveat Emptor. *Pharmacoeconomics*. 2009; 27:179-188.
 44. **Glick HA**. What's in a Perspective? *Value in Health*. 2010; 13:2.
 45. Barbieri M, Drummond D, Rutten F, Cook J, **Glick HA**, Lis J, Reed SD, Sculpher M, Severens J. What Do International Pharmacoeconomic Guidelines Say About Economic Data Transferability? *Value in Health*. 2010;13:1028-37.
 46. **Glick HA**. Sample Size and Power for Cost-Effectiveness Analysis (Part 1). *Pharmacoeconomics*. 2011;29:189-98.
 47. Tsai AG, Wadden TA, Volger S, Sarwar DB, Vetter M, Kumanyika S, Berkowitz RI, Diewald LK, Perez J, Lavenberg J, Panigrahi ER, **Glick HA**. Cost-Effectiveness of a Primary Care Intervention to Treat Obesity. *International Journal of Obesity*. 2013;37:S31-7.
 48. Ramsey SD, Willke RJ, **Glick H**, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-Effectiveness Analysis Alongside Clinical Trials II – An ISPOR Good Research Practices Task Force Report. *Value in Health*. 2015;18:161-72.
 49. Eiraldi R, Khanna MS, Jawad AF, Fishman J, **Glick HA**, Schwartz BS, Cacia J, Wandersman A, Beidas R. A Hybrid Effectiveness-Implementation Trial of Group CBT for Anxiety in Urban Schools: Rationale, Design, and Methods. *Implementation Science*. 2016;11:92.

50. Doshi JA, Miller Sonet Ellen, Puckett JT, **Glick H**. The Need for a New Patient-Centered Decision Tool for Value-Based Treatment Choices in Oncology. Health Affairs Blog, March 19, 2018. DOI: 10.1377/hblog20180309.241877.
51. Doshi JA, Miller-Sonet E, Puckett JT, **Glick HA**. Advocating for New Patient-Centered Tools for Value-Based Treatment Choices in Oncology. Journal of Clinical Pathways. 2019; 5: 44-47.
52. Carhuapoma LR, Kapadia A, **Glick HA**, Hanley DF. What is the Price of the Potential for a Meaningful Recovery following Intracerebral Hemorrhage? Journal of Stroke and Cerebrovascular Diseases. 2021; 10:
<https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106017>
53. Eiraldi R, McCurdy BL, Khanna MS, Wolk CB, **Glick HA**, Rabenau-McDonnell QA, Comly R, Rutherford LE, Banks J, Rufe SA, Popkin KM, Wilson T, Henson K, Wandersman A, Jawad AF. Study Protocol: Cluster Randomized Trial of Consultation Strategies for the Sustainment of Mental Health Interventions in Under-Resourced Urban Schools: Rationale, Design, And Methods. BMC Psychology. 2022; 10: 24.
<https://doi.org/10.1186/s40359-022-00733-8>.

Books:

1. **Glick HA**, Doshi JA, Sonnad SS, Polsky D. *Economic Evaluation in Clinical Trials*. Oxford: Oxford University Press, February 2007.
2. **Glick HA**, Doshi JA, Sonnad SS, Polsky D. *Economic Evaluation in Clinical Trials*. Second Edition. Oxford: Oxford University Press, 2015.

Alternative Media: None

Patents: None